Global Oncology
UW Carbone Cancer Center
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

B1G CANCER RESEARCH CONSORTIUM
Teaming up to fight cancer

Global Oncology Symposium 2025

Speaker bios

Syed Nabeel Zafar, MD, MPH
Program Director - Global Oncology, Assistant Professor - Surgical Oncology, University of Wisconsin, Madison.

Dr. Syed Nabeel Zafar is a surgical oncologist and health services researcher whose work focuses on improving cancer and surgical care delivery both locally and globally. His research focuses on advancing cancer surgery and health systems in low-resource settings. His global oncology research addresses disparities in patient outcomes and focuses on strengthening cancer care delivery in Pakistan, Sub-Saharan Africa and other low- and middle-income countries.

He leads several initiatives that use health services research and real-world data to improve the quality and accessibility of cancer surgery in underserved regions. His work is supported by competitive funding aimed at building long-term collaborations, enhancing surgical capacity, and generating data to inform policy and practice in global cancer care. Through a Baldwin Wisconsin Idea Endowment grant, his team is collaborating with partners at Hawassa University in Ethiopia and the University Teaching Hospital in Zambia to improve surgical and anesthesia outcomes in Sub-Saharan Africa through locally contextual quality improvement initiatives and systems for collecting and using surgical outcomes data.

Katherine Van Loon

Professor of Clinical Medicine | Director, Global Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center

Dr. Van Loon joined the UCSF faculty in 2012 following an oncology fellowship. She earned her MPH from Yale School of Public Health, then an MD from the Medical College of Georgia. She trained in internal medicine at Beth Israel Deaconess Medical Center (Harvard) before her oncology fellowship at UCSF.

As Director of UCSF's Global Cancer Program, Dr. Van Loon leads a diverse portfolio of research, capacity-building, and training initiatives in low- and middle-income countries. She is principal investigator of a U.S. NIH-funded D43 award establishing Tanzania's first cancer research training program and leads studies with partners like Muhimbili University and Ocean Road Cancer Institute to investigate esophageal squamous cell carcinoma in East Africa. In Mexico and the U.S., she studies early-onset colorectal cancer and its impact on Black, Latinx, and Mexican-American populations. In November 2024, Dr. Van Loon was named editor-in-chief of JCO Global Oncology, a global, open-access journal of the American Society of Clinical Oncology, starting February 2025. Her work has been recognized with numerous accolades, including the ASCO Young Investigator Award (2012), UCSF mentoring awards, and leadership honors from WomenLift Health. A member of AORTIC and founding member of AfrECC, she has co-authored over 100 peer-reviewed publications. Dr. Van Loon's research combines epidemiology, public health, and clinical oncology to improve outcomes for gastrointestinal cancers across diverse global settings, with a strong emphasis on training emerging investigators and building sustainable, equitable cancer care systems.

Peter Kingham, MD, FACS
Hepatopancreatobiliary Surgical Oncologist, Director, Global Cancer Disparities Initiative, Co-Founder, Surgeons OverSeas

Dr. Kingham earned his BA from Yale and MD from SUNY Stony Brook. He completed general surgery residency at NYU and a two-year surgical oncology fellowship at MSKCC, where he now performs over 200 liver and pancreas operations annually and directs minimally invasive and image-guided ablation techniques. Since 2007, Dr. Kingham has committed his career to improving cancer surgery in low-resource settings, with extensive fieldwork in Tanzania, Malawi, Nigeria, Sierra Leone, South Africa, and Mexico. He co-founded Surgeons OverSeas (SOS) and serves as its president, working to support surgical capacity and training globally. In 2015, he was appointed Director of MSK's Global Cancer Disparities Initiative. Through this role, Dr. Kingham co-founded the African Research Group for Oncology (ARGO), a consortium of five Nigerian cancer centers and MSK, and leads NIH-funded UG3/UH3 and R01 grants targeting colorectal and breast cancer disparities in West Africa.

Dr. Kingham is Director of MSK's International Surgical Oncology Global Cancer Disparities Fellowship, a year-long program combining clinical and research training in both high- and low-income countries. With more than 300 publications and 18 book chapters, and frequent international lectures, his scholarly work focuses on adapting surgical oncology to resource-constrained environments. A passionate advocate, surgical innovator, and educator, Dr. Kingham brings first-hand experience and data-driven insights on how to build equitable, sustainable cancer care systems globally.

Wilfred Ngwa

Associate Professor, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University

Prof. Wil Ngwa is Founding Director of the Global Health Catalyst summits at Harvard and Johns Hopkins. He leads development of transformative healthcare programs at the United States Advanced Research Project's Agency for Health (ARPA-H). He is a pioneer of the Comprehensive Cancer Center in the Cloud (C4) powered by AI and co-founder of the global oncology university the education component of the C4, training tens of thousands of oncology health professionals and supporting the establishment of comprehensive cancer centers of excellence in different Low- and Middle-Income Countries. His academic service includes serving as ICTU Distinguished Professor of Public Health, as Rutgers Presidential Fellow and Professor of Global Health and Radiation Oncology, as Guest Professor at University of Heidelberg Germany, and visiting Professor at the University of Pennsylvania. He is Co-chair of the Africa-Oxford-Harvard-Hopkins Clinical trials network. He has served as Chair of the Lancet Oncology Commission for sub-Saharan Africa. Prof Ngwa has received over 45 prestigious awards/honors at Harvard, Johns Hopkins, international professional societies and other organizations for his leading efforts in global health, service and cancer research. He served as advisor to the White House on the Cancer Moonshot and in 2025, he won the USA President's Lifetime Achievement Award. He completed his undergraduate studies in Cameroon, graduate studies in physics at the University of Leipzig Germany and completed his clinical training in radiation oncology medical physics at MD Anderson Cancer Center, and Harvard Medical School USA.

Sudha Sivaram

Program Director, Center for Global Health at the National Cancer Institute (NCI).

Dr. Sudha Sivaram is a Program Director and leads the portfolio of global cancer research training at the Center for Global Health at the National Cancer Institute (NCI). In this capacity, she works with colleagues across NCI and the National Institutes of Health (NIH) to develop funding initiatives, and coordinate training and research education programs that seek to build capacity and support career development of early-stage scientists committed to global cancer research. She led the development of NCI's first broad global research training initiative. Dr. Sivaram is a member of several NCI and NIH-wide committees that focus on advancing science in key research areas such as implementation science in cancer control, obesity, and cancer survivorship.

Dr. Sivaram earned her doctorate in public health and epidemiology from the Johns Hopkins University Bloomberg School of Public Health. Following her doctoral degree, she continued at Hopkins serving as Faculty in the Department of Epidemiology where her research in HIV/AIDS and cancer control in south Asia was supported by the US National Institutes of Health as well as private non-profit foundations. Employing principles of social science research, epidemiology and implementation research, Dr. Sivaram's has led and co-authored numerous peer-reviewed publications and book chapters and is a reviewer for many professional journals. She serves as a mentor to students in public health, continues to pursue academic teaching, and currently serves as an Academic Editor for the journal, PLOS Global Public Health. She recently completed a Fullbright-Nehru academic research fellowship in India whose goal was to work with cancer survivors and their care givers to understand patient-reported measures to improve quality of life during and after cancer treatment.

Mark Parascandola, Ph.D., M.P.H.
Branch Director, Research and Training, Center for Global Health, National Cancer Institute (NCI)

Dr. Mark Parascandola is the Director of the Research and Training Branch at the National Cancer Institute's (NCI) Center for Global Health, where he leads initiatives to strengthen research capacity and advance cancer prevention and control worldwide. With over fifteen years of experience in epidemiology, cancer prevention, and global health, his work has focused on implementation science and tobacco control in low- and middle-income countries.

He has authored more than 75 publications and served as an editor for several landmark reports, including The Economics of Tobacco and Tobacco Control (NCI/WHO, 2016), Smokeless Tobacco and Public Health: A Global Perspective (NCI/CDC, 2014), and the two-volume encyclopedia Tobacco: Its History and Culture (2005). Dr. Parascandola has also represented NCI as an Embassy Science Fellow and expert advisor on tobacco control, air pollution, and health at U.S. embassies in Beijing, China, and Warsaw, Poland.

Dr. Parascandola holds a Ph.D. in Philosophy of Science from the University of Cambridge and an M.P.H. in Epidemiology from Johns Hopkins University. His work continues to bridge scientific evidence, policy, and capacity building to advance equitable cancer control globally.

Nita Ahuja, MD, MBA
Dean of the School of Medicine and Public Health, UW School of Medicine and Public Health

Nita Ahuja, MD, MBA, is the dean of the University of Wisconsin School of Medicine and Public Health and UW–Madison's vice chancellor for medical affairs. She also serves as rotating chair or vice chair of the board of the UW Hospitals and Clinics Authority and is a professor in the Department of Surgery. Ahuja holds the Robert Turell Distinguished Chair in Medical Leadership. Ahuja is a board member of the Association of American Medical Colleges (AAMC), the representative body serving all accredited U.S. and Canadian medical schools and teaching hospitals, and chair of the AAMC's Council of Faculty and Academic Societies. She is an elected member of the National Academy of Medicine and a fellow of the American College of Surgeons.

Ahuja is a cancer-care innovator whose treatment approaches and research have garnered international recognition. She is an expert in the treatment of sarcomas and complex gastrointestinal cancers, and her innovative surgical and heated chemotherapy approaches have drawn patients from around the world seeking treatment for difficult metastatic cancers.

A passionate advocate for interdisciplinary approaches to medicine and translating discoveries into treatments, Ahuja has a long history of leading collaborative and cutting-edge research aimed at improving cancer outcomes. Her research laboratory identifies and develops biomarkers to allow early detection of pancreatic and colorectal cancers using patients' genetic information. She has published more than 300 scholarly articles and book chapters to advance both the surgical and basic science fields.

Patrick J. Loehrer, Sr., M.D.
Distinguished Professor of Medicine, Joseph W. and Jackie J. Cusick Professor in Oncology
Director IUSCCC Center of Global Oncology, Indiana University School of Medicine



Dr. Patrick J. Loehrer is Distinguished Professor of Medicine at the Indiana University School of Medicine. A pioneering oncologist and visionary leader, Dr. Loehrer has dedicated his career to advancing equitable cancer care through research, education, and global collaboration.

As the former Director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC), Dr. Loehrer led the institution to achieve Comprehensive Cancer Center designation by the National Cancer Institute. He also founded the Academic Model Providing Access to Healthcare (AMPATH)-Oncology Program, a groundbreaking partnership between North American institutions and Moi University in Kenya that has transformed cancer care delivery in Western Kenya—expanding access to diagnostics, chemotherapy, radiation, and training for local clinicians.

Now serving as Director of the Center for Global Oncology at Indiana University, Dr. Loehrer continues to champion sustainable, patient-centered approaches to cancer care in resource-limited settings. His philosophy of “leading with care” emphasizes that global oncology partnerships must first and foremost improve patient outcomes while fostering mutual learning and capacity building.

A recognized expert in thymic, gastrointestinal, and genitourinary malignancies, Dr. Loehrer has authored numerous clinical trials and publications that have shaped modern oncology practice. His contributions have earned him multiple honors, including the Allen S. Lichter Visionary Leader Award and the Humanitarian Award from the American Society of Clinical Oncology (ASCO).

Christian Capitini, M.D.
Professor and Division Chief, Hematology, Oncology, Transplant, and Cellular Therapy
Jean R. Finley Professor in Pediatric Hematology and Oncology
Acting Director, University of Wisconsin Carbone Cancer Center

Dr. Christian Capitini is Professor and Division Chief in the Department of Pediatrics at the University of Wisconsin, as well as the Acting Director of the UW Carbone Cancer Center. He leads groundbreaking research and clinical programs in cellular immunotherapy, including CAR T-cell and natural killer (NK) cell therapies, focused on pediatric and adult cancers, particularly solid tumors and hematologic malignancies.

Dr. Capitini's laboratory develops innovative cell-based therapies to treat cancers such as neuroblastoma, osteosarcoma, and rhabdomyosarcoma, and to address complications from stem cell transplantation, including graft-versus-host disease. He was one of 13 U.S. site Principal Investigators for the first multicenter CD19 CAR T-cell trial that led to FDA approval of tisagenlecleucel (Kymriah) for relapsed/refractory B-cell leukemia. He also leads multiple ongoing trials expanding CAR T-cell and other cellular therapies to pediatric and adult cancers. Nationally, Dr. Capitini is an active leader in the Society for Immunotherapy of Cancer and serves on the executive board of the Pediatric Real World CAR T Consortium. He is also a section editor for the Journal for Immunotherapy of Cancer.

Dr. Capitini's commitment to collaboration and mentorship, along with his dedication to translating innovative research into patient-centered care, exemplifies his leadership in advancing global oncology and immunotherapy.

Thomas S. Uldrick, MD MS
Affiliate Professor, Fred Hutchinson Cancer Center

Thomas S. Uldrick, MD MS is a medical oncologist, physician-scientist, and drug developer with over 18 years of clinical research experience across government, academia, and industry. His expertise includes immunotherapy clinical trials and cancer treatment in people living with HIV.

Dr. Uldrick served as Principal Investigator for a landmark trial demonstrating the safety of anti-PD1 immunotherapy in individuals with HIV and cancer, and its activity in HIV-associated Kaposi sarcoma. In collaboration with the Uganda Cancer Institute, he led a study showing the feasibility of achieving excellent outcomes using rituximab-based therapy for diffuse large B-cell lymphoma in Uganda.

He chaired the ASCO–Friends of Cancer Research HIV Working Group focused on modernizing clinical trial eligibility and serves on the Society for Immunotherapy of Cancer's Global Access and Impact Committee.

Dr. Uldrick is currently at Regeneron, where he leads immunotherapy clinical trials targeting multiple solid tumors.

Shannon O'Reilly, Ph.D.
Associate Professor, Department of Human Oncology
University of Wisconsin Carbone Cancer Center

Dr. Shannon O'Reilly is an Associate Professor in the Department of Human Oncology at the University of Wisconsin and a member of the UW Carbone Cancer Center. Her work focuses on radiation therapy, functional lung imaging, and strategies to reduce radiation-induced toxicities, with a particular emphasis on global oncology and education.

Dr. O'Reilly has been deeply engaged in capacity-building initiatives in low- and middle-income countries, including the development of online training platforms and clinical rotations for medical physics trainees in Ghana. Currently, she is applying for funding to develop public education programs focused on cancer prevention and HPV vaccination in Ghana, recognizing the critical importance of community engagement in global cancer control.

An advocate for mentorship and global collaboration, Dr. O'Reilly serves as an International Council Associates Mentorship Program mentor and Vice-Chair of the Global Medical Physics Education and Training Committee of the American Association of Physicists in Medicine (AAPM). She is also actively involved in outreach initiatives to expand the medical physics pipeline.

Passionate about bridging disciplines, borders, and experience levels, Dr. O'Reilly emphasizes that effective global oncology requires understanding local infrastructure and barriers, designing practical solutions, and fostering lasting collaborations.

Taylor Jaraczewski, M.D.
Surgery Resident & Global Surgery Research Fellow
Medical College of Wisconsin

Dr. Jaraczewski is a surgery resident in the Department of General Surgery at the Medical College of Wisconsin and the inaugural Global Surgery Research Fellow. He is also the second fellow of the American College of Surgeons' Health and Outreach Program for Equity (H.O.P.E.) in global surgery and a resident physician researcher in the AN.AI Lab.

A Gurnee, IL native, Dr. Jaraczewski earned undergraduate and master's degrees in biomedical engineering from the University of Wisconsin–Madison, a master's in global health equity from the Medical College of Wisconsin, and his medical degree from Loyola University Chicago Stritch School of Medicine.

His research focuses on leveraging machine learning, artificial intelligence, and mixed-methods approaches to enhance surgical quality and access in resource-constrained settings. He is the principal investigator of a surgical data collection project in Ethiopia and co-investigator on a project optimizing care for uninsured patients in Milwaukee. With multiple publications and grants in these areas, Dr. Jaraczewski plans to pursue a fellowship in surgical oncology, aiming to advance surgical and oncologic care for patients regardless of socioeconomic or geographic barriers.

Minh Tung Phung, PhD, MPH
Assistant Professor of Population Health Sciences, University of Wisconsin, Madison

Dr. Phung is a cancer epidemiologist. His research interests span across the cancer continuum, including cancer etiology, prevent ion, and survivorship. Dr. Phung's research has focused on (1) establishing new population-based studies to study cancer risk and survivorship, (2) developing and validating models for precision medicine in cancer, and implementing these models into clinical practice; (3) partnering with communities to develop and implement evidence-based and scalable interventions to improve cancer screening and health equity in underserved populations both in the US and globally. Dr. Phung's research has specifically focused on women's cancers, including breast, cervical, endometrial, and ovarian cancers.

Juliet S. Lumati, MD, MPH
Assistant Professor of Surgical Oncology
Northwestern University Feinberg School of Medicine; Member, Robert H. Lurie Comprehensive Cancer Center and the Robert J. Havey, MD Institute for Global Health's joint Center for Global Oncology

Dr. Juliet S. Lumati is an assistant professor of Surgical Oncology at Northwestern University Feinberg School of Medicine and a member of the Robert H. Lurie Comprehensive Cancer Center and the Robert J. Havey, MD Institute for Global Health's joint Center for Global Oncology. She is dedicated to improving access to cancer care in low- and middle-income countries (LMICs), particularly in Sub-Saharan Africa. Her research focuses on healthcare financing, financial navigation programs, and their impact on treatment adherence and financial toxicity among cancer patients.

Dr. Lumati is the principal investigator of the COST-FIN trial, a randomized controlled study evaluating the effectiveness of a financial navigation program in reducing financial distress and improving treatment adherence for cancer patients in Nigeria. Her contributions to global oncology have been recognized with the 2025 Global Oncology Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). Additionally, Dr. Lumati is a member of the African Research Group for Oncology (ARGO), an NCI-recognized collaborative research consortium in Africa, and has served as a part-time surgical oncology consultant at Lakeshore Cancer Center, Nigeria's first comprehensive cancer center. With over a decade of experience in global health, Dr. Lumati continues to work towards strengthening multidisciplinary cancer care in LMICs through innovative healthcare financing strategies.

Stephen Avery, PhD
Professor of Radiation Oncology, Hospital of the University of Pennsylvania

Dr. Stephen Avery is a Professor of Radiation Oncology at the University of Pennsylvania, where he also serves as Director of Global Radiation Physics. He earned his PhD in Experimental Nuclear Physics from Hampton University and has more than two decades of experience in medical physics education, research, and global capacity building.

A Fellow of the American Association of Physicists in Medicine (AAPM), Dr. Avery is the Principal Investigator of the NIH R25 AMPERE (Access for Medical Physicists to Education and Research Excellence) global program, a former Program Director of the UPenn Medical Physics Graduate Program, a former Member-at-Large of the AAPM Board of Directors, a past member of the Commission on Accreditation of Medical Physics Education Programs (CAMPEP), and the inaugural Chair of the AAPM International Council's Global Medical Physics Education and Training Committee. His leadership extends across Africa, Asia, Latin America and the Caribbean, where he has worked to expand equitable access to radiation oncology education, technology, and infrastructure.

Dr. Avery co-convenes the Medical Physics Group within the African Strategy for Fundamental and Applied Physics (ASFAP) and serves on advisory panels for organizations including the NIH, The Lancet Oncology Commission, and the African Organization for Research and Training in Cancer (AORTIC). He is also Co-Director of the Global Health Catalyst Summit, leading international initiatives focused on oncology education, including the development of VR/AI-based training platforms and academic–industry partnerships.

His work has been published in The Lancet Oncology, Medical Physics, and Radiotherapy & Oncology, and he lectures internationally on global health, proton therapy, and workforce development in medical physics.

Muhammad Murtaza, MD, PhD
Associate Professor, Division of Surgical Oncology, Director, Center for Human Genomics and Precision Medicine, University of Wisconsin, Madison

Dr. Muhammed Murtaza holds his MBBS from Aga Khan University and earned his PhD in Medical Science from the Cancer Research UK Cambridge Institute at the University of Cambridge. He serves as Associate Professor in the Division of Surgical Oncology and directs the Center for Human Genomics and Precision Medicine. His research is centered on the development of novel diagnostics harnessing tumor-derived cell-free DNA and fragmentomic signatures for early cancer detection and precise monitoring of metastatic disease. Notably, his team's publication "Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer" garnered the 2024 Bothwell Prize, awarded by the UW Carbone Cancer Center and McArdle Laboratory for Cancer Research.

In recognition of his translational work to enable accessible, at-home blood-based cancer screening, he was named a 2024 recipient of the Wisconsin Alumni Research Foundation (WARF) Innovation Award for "Simplifying the Process for Early Detection, Screening of Cancer". Dr. Murtaza's ongoing projects include a National Cancer Institute UH3 Cooperative Award to advance cutting-edge genomics platforms for cancer detection, and a pilot initiative with Dr. Zafar to assess tumor DNA in peritoneal fluid as a biomarker of metastatic gastrointestinal cancers.

Through his leadership, his lab bridges genomic innovation with clinical oncology to accelerate early-detection paradigms and precision medicine strategies for patients both locally and globally.

Cibele Barbosa Carroll, MD, PhD, MPH
Scientist II, Survivorship Research Program and Cancer Health Disparities Initiative, University of Wisconsin, Madison

Dr. Cibele Barbosa Carroll is a clinician-scientist with a unique international background and a strong commitment to cancer survivorship, health services research, and global oncology. She earned her MD, PhD, and MPH, and brings experience both as a practicing surgical oncologist in Brazil and as an investigator at the University of Wisconsin Carbone Cancer Center (UWCCC) in Madison, Wisconsin. Carbone Cancer Center.

From 2009 to 2018, Dr. Carroll served as a gastrointestinal surgical oncologist at the Brazilian National Cancer Institute (INCA), where her clinical focus included colorectal and pancreatic cancer surgery and efforts to improve care pathways in Brazil. At UWCCC, she is affiliated with the Survivorship Research Program and the Cancer Health Disparities Initiative. Her research spans cancer survivorship care, disparities in oncology access and outcomes, the development of oncology data capture systems, and global collaborations, particularly between Brazil and the U.S.

In her work on survivorship, Dr. Carroll investigates how health services, system-level barriers, and socioeconomic context shape long-term outcomes for cancer patients both domestically and internationally. She has published on topics such as colorectal cancer mortality trends, area-level socioeconomic factors, and structured oncology data capture to support real-world evidence and equity-oriented research. Widely recognized for bridging clinical oncology, global health, and health systems research, Dr. Carroll is well poised to advance how we understand and address survivorship, disparities, and care delivery across diverse settings.

Robert Striker, MD, PhD
Associate Professor, Infectious Disease, University of Wisconsin, Madison

Dr. Robert Striker is a faculty member in the Division of Infectious Disease within the Department of Medicine. During his MD/PhD training at Washington University, his thesis work with Dr. Scott Hultgren focused on understanding and blocking the critical P pili attachment factors needed for most urinary tract infections. He completed his internal medicine residency in San Francisco, California at a time when combination antiretroviral therapy regimes were greatly reducing mortality of the HIV epidemic. During his clinical fellowship training at Stanford University, he also conducted postdoctoral research with Dr. Karla Kirkegaard on Hepatitis C Virus (HCV). Upon joining the faculty of UW-Madison, his initial work focused on improving antiviral therapy for HCV, and specifically the role of phosphorylation in flaviviral life cycles. His research group demonstrated that phosphorylation events contribute to mosquito-mediated spread of Dengue and other flaviviruses. More recently, he has focused on developing kinase inhibitors for viral and bacterial infections, particularly PASTA kinase inhibitors that can sensitize gram positive infections to beta lactam antibiotics as well as efforts to quantify and shrink the HIV reservoir as a means of lessening immune dysfunction that accompanies HIV infection. Dr. Striker's research has been supported by funding from the National Institutes of Health, the American Cancer Society, the Hartwell Foundation, the Wisconsin Partnership Program, the UW Institute for Clinical and Translational Research, and the Veteran's Association. He is also the Course Director for a multidisciplinary course for medical students, nurse practitioner students, physician assistant students, and pharmacy students who are interested in improving care for those that are incarcerated.

As a physician-scientist, Dr. Striker's approach combines clinical insights with advances from basic and translational research to improve the treatment of infectious diseases. He is a member of the American Association of the Study of Liver, the American Society of Transplantation, a founding member of the National Hepatitis in Corrections Network, and a fellow of the Infectious Diseases Society of America.

Krishnau Saha
Professor, Biomedical Engineering University of Wisconsin, Madison

Dr. Krishanu Saha is a professor of Biomedical Engineering, Pediatrics, and Bioethics at the University of Wisconsin–Madison, holding the Kathryn & Latimer Murfee Chair at the McPherson Eye Research Institute.

At UW–Madison, Saha leads the Saha Lab, where his research spans human stem cell engineering, non-viral genome editing platforms, biomaterials, and the biomanufacturing of cell therapies. His work includes leadership within large consortia such as the NIH Somatic Cell Genome Editing Consortium, and development of next-generation CRISPR and cell-therapy manufacturing technologies. Dr. Saha also integrates a rich interdisciplinary lens: alongside his engineering and biomedical work, he engages deeply with the ethics, policy, and governance of genome editing and cell therapies, drawing on his affiliation with the Holtz STS Center and Bio+Society Collaboratory.

His global outlook is informed by personal roots, his parents emigrated from Kolkata, India and his commitment to building bridges between high-tech biomedical engineering and global health contexts. Saha's contributions have been widely recognized: in 2023 he was named a H.I. Romnes Faculty Fellow in recognition of his research excellence and translational impact.

With more than 100 peer-reviewed publications, multiple patents, and leadership in biomanufacturing initiatives, his work situates him at the nexus of engineering, medicine, and ethics, charting paths from bench to bedside and policy.